Treatment of Grade 2–3, Clear Cell, or Pelvic/Axial Skeleton Chondrosarcoma

This protocol addresses conventional chondrosarcoma in subtypes that carry higher oncologic risk: grade 2 or 3 disease, clear cell chondrosarcoma, and chondrosarcoma arising in the pelvis or axial skeleton. It does not apply to dedifferentiated, mesenchymal, or skull base variants.

Higher-grade chondrosarcomas — including clear cell subtype — and all chondrosarcomas of the pelvis or axial skeleton are associated with increased risk of incomplete resection, local recurrence, and distant spread. Wide surgical margins are the established priority for these subtypes.

Treatment approach (partial)

For patients with limited metastatic spread to the lungs, a surgical or ablative strategy targeting those lesions is among the management considerations. Beyond local disease control, systemic therapy with documented activity in conventional chondrosarcoma may play a role — the complete regimen and decision algorithm are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

Higher-grade chondrosarcomas (including clear cell chondrosarcoma) and all chondrosarcomas of the pelvis or axial skeleton should be surgically removed with wide margins.
Surgery or local ablation should be considered for oligometastatic pulmonary disease.
Pazopanib has demonstrated activity in conventional chondrosarcoma.

DOI: 10.1038/s41416-024-02868-4

View source ↗